(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The study met its primary endpoint, with statistically significant improvement ...
MedPage Today on MSN
Managing myasthenia gravis during pregnancy
Women benefit from planning before conception ...
Updates on the efficacy of new and emerging therapies for myasthenia gravis (MG) presented at the American Association of Neuromuscular and Electrodiagnostic Medicine 2025 Annual Meeting are discussed ...
Richard J. Nowak, MD, is director of the Myasthenia Gravis Clinic, director of Clinical & Translational Neuromuscular Research (CTNR), and associate professor of neurology at Yale School of Medicine.
SAN FRANCISCO — Efgartigimod (Vyvgart), a neonatal Fc receptor (FcRn) antagonist, significantly improved symptoms in patients with anti-acetylcholine receptor antibody (AChR-Ab)-negative generalized ...
The FDA expanded the indication of inebilizumab (Uplizna) to include generalized myasthenia gravis (gMG), Amgen announced Friday. The drug is now approved to treat gMG in adults who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results